ImmunoPrecise Antibodies (IPA) Projected to Post Earnings on Friday

ImmunoPrecise Antibodies (NASDAQ:IPA) is expected to be announcing its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $6.59 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

ImmunoPrecise Antibodies Stock Performance

Shares of NASDAQ:IPA opened at $0.43 on Thursday. The business has a 50-day moving average of $0.44 and a two-hundred day moving average of $0.48. The firm has a market capitalization of $13.28 million, a PE ratio of -0.55 and a beta of 0.09. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $1.64.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of ImmunoPrecise Antibodies in a report on Friday, March 14th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.